×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
NASDAQ:PROG

Progenity (PROG) Stock Forecast, Price & News

$0.80
+0.01 (+1.27%)
(As of 05/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.77
$0.86
50-Day Range
$0.69
$1.69
52-Week Range
$0.66
$6.20
Volume
1.52 million shs
Average Volume
8.59 million shs
Market Capitalization
$147.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.03
30 days | 90 days | 365 days | Advanced Chart
Receive PROG News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenity and its competitors with MarketBeat's FREE daily newsletter.

Progenity logo

About Progenity

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Headlines

Progenity Q1 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PROG
Fax
N/A
Employees
124
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.25 million
Book Value
($0.52) per share

Profitability

Net Income
$-247.41 million
Net Margins
-966.23%
Pretax Margin
-14,325.58%

Debt

Price-To-Earnings

Miscellaneous

Free Float
38,129,000
Market Cap
$147.36 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/28/2022
Today
5/26/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

329th out of 1,424 stocks

Medical Laboratories Industry

11th out of 33 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -













Progenity (NASDAQ:PROG) Frequently Asked Questions

Is Progenity a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenity in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Progenity stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROG, but not buy additional shares or sell existing shares.
View analyst ratings for Progenity
or view top-rated stocks.

When is Progenity's next earnings date?

Progenity is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Progenity
.

How were Progenity's earnings last quarter?

Progenity, Inc. (NASDAQ:PROG) released its earnings results on Monday, March, 28th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.08. The firm had revenue of $0.44 million for the quarter. During the same period in the prior year, the company posted ($1.53) earnings per share.
View Progenity's earnings history
.

What price target have analysts set for PROG?

5 equities research analysts have issued 12-month price targets for Progenity's shares. Their forecasts range from $2.00 to $42.00. On average, they anticipate Progenity's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 1,556.3% from the stock's current price.
View analysts' price targets for Progenity
or view top-rated stocks among Wall Street analysts.

Who are Progenity's key executives?
Progenity's management team includes the following people:
  • Mr. Eric d'Esparbes, Chief Financial Officer (Age 54, Pay $602.67k)
  • Mr. Aditya P. Mohanty, CEO & Director (Age 55)
  • Eric Fox, VP of Fin. & Accounting & Treasurer
  • Dr. Matthew T. Cooper M.B.A., Ph.D., Chief Scientific Officer (Age 49)
  • Mr. Troy Seelye, Chief Information Officer (Age 58)
  • Mr. Clarke Neumann, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Mr. George Gianakopoulos, Sr. VP of Sales (Age 60)
  • Ms. Robyn Hatton, VP of HR
  • Mr. Sami Shihabi M.B.A., M.S., Chief Commercial Officer (Age 50)
  • Mr. Kevin Howe Ph.D., Sr. VP of Strategic Operations
What other stocks do shareholders of Progenity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenity investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Enphase Energy (ENPH), Kandi Technologies Group (KNDI), Trevena (TRVN), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC) and DRDGOLD (DRD).

When did Progenity IPO?

(PROG) raised $100 million in an initial public offering on Friday, June 19th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Raymond James and BTIG were co-managers.

What is Progenity's stock symbol?

Progenity trades on the NASDAQ under the ticker symbol "PROG."

Who are Progenity's major shareholders?

Progenity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.80%), Jane Street Group LLC (0.00%), State Street Corp (0.24%), Group One Trading L.P. (0.00%), Virtu Financial LLC (0.20%) and Commonwealth Equity Services LLC (0.07%). Company insiders that own Progenity stock include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli and Jeffrey D Alter.
View institutional ownership trends for Progenity
.

Which major investors are selling Progenity stock?

PROG stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, and HAP Trading LLC.
View insider buying and selling activity for Progenity
or view top insider-selling stocks.

Which major investors are buying Progenity stock?

PROG stock was bought by a variety of institutional investors in the last quarter, including Group One Trading L.P., Virtu Financial LLC, Vanguard Group Inc., State Street Corp, Jane Street Group LLC, Commonwealth Equity Services LLC, and Independent Advisor Alliance. Company insiders that have bought Progenity stock in the last two years include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli, and Jeffrey D Alter.
View insider buying and selling activity for Progenity
or or view top insider-buying stocks.

How do I buy shares of Progenity?

Shares of PROG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Progenity's stock price today?

One share of PROG stock can currently be purchased for approximately $0.80.

How much money does Progenity make?

Progenity has a market capitalization of $147.36 million and generates $1.25 million in revenue each year. The company earns $-247.41 million in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Progenity have?

Progenity employs 124 workers across the globe.

What is Progenity's official website?

The official website for Progenity is www.progenity.com.

How can I contact Progenity?

Progenity's mailing address is 4330 LA JOLLA VILLAGE DRIVE SUITE 200, SAN DIEGO CA, 92122. The company can be reached via phone at 855-293-2639 or via email at [email protected].

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]t.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.